Agree completely. The market cap is ridiculous here and there are plenty of OTC stocks trading 5-10 million valuation with no IP, no significant assets; let alone an extremely promising drug candidate that has progressed to final preclinical stages within the NIH program to mitigate the opioid crisis! amongst other promising drug candidates!
Couple that with new VP and institutional debt getting shares at .0015 and some preclinical acquisitions and deals in the pharma business netting 100s of millions, this truly becomes a no brainer!
News 
Market Data 
Discover 
